Exogenous expression of TM1 is insufficient to restore normal actin cytoskeleton structure in neuroblastoma cells, highlighting cell-type specific responses to cytoskeletal modulation in cancer.
Answers are grounded in this paper and cite their sources.
TM1 insufficiency in neuroblastoma models highlights cell-type specificity; leaves open targeted cytoskeletal strategies in cancer.
Tropomyosin 1 (TM1) is downregulated in a number of transformed cell types, and exogenous expression of TM1 can restore actin organisation and reverse cellular transformation. We find that TM1 is also downregulated in human neuroblastoma cell lines, correlating with increasing malignancy. However, exogenous TM1 does not restore actin cytoskeleton organisation in neuroblastoma cells.
No takes yet. Share an insight, caveat, or question.
Yager et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: